What is the primary driver of Intuitive Surgical's revenue growth in the reported quarter?

The primary driver of Intuitive Surgical's revenue growth is the significant increase in the number of da Vinci Surgical Systems sold. In the first quarter of 2001, 12 systems were sold, a substantial increase from only 3 systems sold in the same period of 2000.

Is Intuitive Surgical profitable?

No, Intuitive Surgical is not yet profitable. The company reported a net loss of $3.4 million for the first quarter of 2001, although this is an improvement compared to the $5.0 million net loss reported in the first quarter of 2000. Management expects to incur substantial operating losses for at least the next two years.

What are the major risks highlighted in the Management's Discussion and Analysis?

Key risks highlighted include ongoing patent litigation with Computer Motion and Brookhill-Wilk, the uncertainty of market acceptance for their novel surgical technology, the potential for long and variable sales cycles, reliance on a small number of key customers, regulatory hurdles, manufacturing challenges, and the need for future capital raises.

How is the company managing its cash and liquidity?

As of March 31, 2001, Intuitive Surgical had $76.9 million in cash, cash equivalents, and short-term investments. Management believes these resources, along with expected revenues, are sufficient to fund operations through at least 2002. They are managing liquidity by investing in short-term, liquid securities.

ISRG 10-Q Quarterly Report Q1 FY2001 — Revenue, Net Income, EPS

Summary

Intuitive Surgical, Inc. (ISRG) reported its first-quarter results for the period ending March 31, 2001. The company saw a significant year-over-year increase in sales, primarily driven by a substantial rise in the number of da Vinci Surgical Systems sold, from 3 in Q1 2000 to 12 in Q1 2001. This sales growth led to a substantial improvement in gross profit margin, which increased from 14% to 46%. Despite this revenue growth, the company continues to operate at a net loss, reporting a net loss of $3.4 million for the quarter, an improvement from the $5.0 million loss in the prior year's quarter. This loss is attributed to increased operating expenses, particularly in research and development and selling, general, and administrative functions, which are expanding to support product development and market penetration. The company maintains a strong liquidity position, with $76.9 million in cash, cash equivalents, and short-term investments as of March 31, 2001, which management believes is sufficient to fund operations through 2002. However, significant risks remain, including ongoing patent litigation with Computer Motion and Brookhill-Wilk, potential market acceptance challenges for its novel surgical system, and the inherent uncertainties of scaling manufacturing and sales operations. Investors should note the ongoing strategic investments in R&D and sales infrastructure as the company works towards achieving profitability.

Key Highlights

1Sales surged 312% to $12.1 million in Q1 2001, up from $2.9 million in Q1 2000, driven by a significant increase in da Vinci Surgical System unit sales (12 vs. 3).
2Gross profit margin improved dramatically to 46% ($5.5 million) in Q1 2001, compared to 14% ($0.4 million) in Q1 2000, reflecting economies of scale and manufacturing efficiencies.
3Net loss narrowed to $3.4 million ($0.10 per share) in Q1 2001, an improvement from a net loss of $5.0 million ($0.90 per share) in Q1 2000.
4Operating expenses increased, with R&D up 23% to $3.2 million and SG&A up 118% to $6.8 million, reflecting investments in product development and sales/marketing expansion.
5The company held $76.9 million in cash, cash equivalents, and short-term investments as of March 31, 2001, with management confident in its ability to fund operations through 2002.
6Significant legal proceedings are ongoing with Computer Motion and Brookhill-Wilk concerning patent infringements, posing potential financial and operational risks.
7The company received FDA clearance in March 2001 for non-cardiac thoracoscopic surgical procedures, expanding the potential applications of its da Vinci Surgical System.

INTUITIVE SURGICAL INC Quarterly Report for Q1 Ended Mar 31, 2001

Summary

Key Highlights

Frequently Asked Questions